Viridian Therapeutics, Inc. (VRDN) stock analysis

VRDN · Viridian Therapeutics, Inc.

Latest recorded price: USD 29.80

Sector and industry: Healthcare · Biotechnology

Fiscal 2017 figures: revenue growth -14.9%, free cash flow margin -709.8%. The model flags 1 risk signal for this company (1 high severity).

Similar companies in Healthcare